Kidney stones are among the possible risks of GLP-1 use that were not previously known. Glucagon-like peptide 1 receptor agonists (GLP-1RAs) may have a wider range of benefits and risks than what the ...

Obesity is a growing concern worldwide, including in low- and middle-income countries (LMICs). Addressing this issue involves various strategies, including dietary and lifestyle changes, medical ...

HUNTINGTON — GLP-1 agonists like Ozempic, Trulicity, Mounjaro, Victoza and Wegovy started as a way to treat diabetes but have since become popular tools for weight loss. Dr. Matthew Christiansen ...

That is perhaps why there has been so much buzz surrounding the class of drug known as a GLP-1 agonist.

As earlier outlined, short-term studies in animals and humans have shown GLP-1 to have some direct vasorelaxation action, cardioprotective effects in models of ischemia-reperfusion injury ...

New research suggests that Ozempic and similar weight loss medications have the potential to be as big a game changer in ...

A small study of Sanofi’s lixisenatide has suggested that the GLP-1 agonist could slow down the progression of Parkinson’s disease, pointing to another potential use for the fast-growing drug ...

GLP-1: Glucagon-like peptide-1; RA: receptor agonist. ACS: Acute coronary syndrome; CAD: Coronary artery disease; CHF: Congestive heart failure; CRF: Chronic renal ...

The EMA’s safety committee has said that, after a review of available data, it has found no evidence that GLP-1 agonist drugs such ... concluded that the data “does not support a causal ...

Victoza (liraglutide) and Ozempic (semaglutide) are two injectable drugs used to treat people with type 2 diabetes. The drugs, classified as GLP-1 agonists, have also been used for weight loss in ...